Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.56 |
| ▸ | CHUK | O15111 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103455 | 0.92 | IKBKB (0.57) | IKBKBCHUKJAK2TYK2ROCK1 | |
| SCHEMBL5103401 | 0.90 | IKBKB (0.56) | IKBKBCHUKJAK2TYK2ROCK1 | |
| SCHEMBL9989953 | 0.90 | IKBKB (0.59) | IKBKBCHUKJAK2TYK2 | |
| SCHEMBL5113373 | 0.89 | IKBKB (0.55) | IKBKBCHUKJAK2TYK2ROCK2 | |
| SCHEMBL5105979 | 0.89 | IKBKB (0.56) | IKBKBCHUKJAK2TYK2 | |
| SCHEMBL5112204 | 0.89 | IKBKB (0.56) | IKBKBCHUKJAK2TYK2 | |
| SCHEMBL5105463 | 0.88 | IKBKB (0.55) | IKBKBCHUKJAK2TYK2ROCK2 | |
| SCHEMBL5098773 | 0.88 | IKBKB (0.55) | IKBKBCHUKJAK2TYK2 | |
| SCHEMBL5103563 | 0.88 | IKBKB (0.55) | IKBKBCHUKJAK2TYK2 | |
| SCHEMBL5102870 | 0.87 | IKBKB (0.58) | IKBKBCHUKJAK2TYK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833836-B1 | IMIDAZO-FUSED THIAZOLO [4,5-B] PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7456194-B2 | Imidazo-fused oxazolo [4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060106051-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106051-A1 | Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, IRAK4, P2RX7 | IKBKB 131/4885CHUK 237/4885JAK2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.